Summary
Abbott Laboratories reported a net sales decrease of 11.4% to $9.98 billion for the second quarter of 2023, largely driven by a significant decline in COVID-19 testing sales. Excluding COVID-19 testing and the impact of foreign exchange, total net sales grew by 11.9%. The Medical Devices segment showed robust growth, increasing 13.5% (15.4% excluding foreign exchange), bolstered by strong performance in Diabetes Care and contributions from recent acquisitions. The Diagnostic segment experienced a substantial decline of 46.0% (44.7% excluding foreign exchange), primarily due to lower demand for COVID-19 tests. Net earnings for the quarter decreased to $1.375 billion ($0.78 per diluted share) from $2.018 billion ($1.14 per diluted share) in the prior year. This decline reflects the reduced sales from COVID-19 diagnostics and increased operating costs, partly offset by the acquisition of Cardiovascular Systems, Inc. (CSI) and ongoing margin improvement initiatives. Despite the top-line contraction driven by the normalization of COVID-19 testing, Abbott's core businesses continue to demonstrate resilience and growth, particularly in its Medical Devices segment.
Financial Highlights
51 data points| Revenue | $9.98B |
| Cost of Revenue | $4.48B |
| Gross Profit | $5.50B |
| R&D Expenses | $715.00M |
| SG&A Expenses | $2.74B |
| Operating Expenses | $8.44B |
| Operating Income | $1.54B |
| Interest Expense | $159.00M |
| Net Income | $1.38B |
| EPS (Basic) | $0.79 |
| EPS (Diluted) | $0.78 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Total net sales for Q2 2023 were $9.98 billion, a decrease of 11.4% (8.9% excluding foreign exchange), primarily due to a significant drop in COVID-19 testing sales.
- 2Excluding COVID-19 testing sales and foreign exchange impacts, Abbott's total net sales increased by 11.9% year-over-year.
- 3The Medical Devices segment demonstrated strong performance, with net sales growing 13.5% (15.4% excluding foreign exchange), driven by double-digit growth in Diabetes Care and other key areas.
- 4The Diagnostic Products segment saw a significant decline of 46.0% (44.7% excluding foreign exchange) due to decreased demand for COVID-19 tests.
- 5Net earnings for Q2 2023 were $1.375 billion ($0.78 diluted EPS), down from $2.018 billion ($1.14 diluted EPS) in Q2 2022.
- 6Abbott acquired Cardiovascular Systems, Inc. (CSI) for $851 million in April 2023, expanding its vascular device offerings.
- 7The company repurchased approximately 7 million shares for $725 million in the first six months of 2023 and maintained a strong balance sheet with $7.8 billion in cash and cash equivalents as of June 30, 2023.